Search Results - "Belluomini, L"

Body composition as a modulator of response to immunotherapy in lung cancer: time to deal with it by Trestini, I., Caldart, A., Dodi, A., Avancini, A., Tregnago, D., Sartori, G., Belluomini, L., Milella, M., Pilotto, S.

Get full text

A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT study by Avancini, A., Giannarelli, D., Borsati, A., Carnio, S., Cantale, O., Nepote, A., Mangiapane, F., Bafunno, D., Galetta, D., Longo, V., Tregnago, D., Trestini, I., Belluomini, L., Sposito, M., Insolda, J., Schena, F., Milella, M., Novello, S., Pilotto, S.

“…Evidence demonstrates that physical exercise confers several psycho-physical benefits on patients with cancer. This study aims to investigate the role of…”
Get full text

Efficacy of anti-EGFR antibodies combined with chemotherapy for elderly patients with RAS wild-type metastatic colorectal cancer: a systematic review and metanalysis by Carandina, I., Belluomini, L., Bonetti, F., Urbini, B., Daniel, F., Lancia, F., Martella, L.R., Toma, I., Moretti, A., Bannò, E., Nisi, C., Da Ros, L., Frassoldati, A.

Get full text

The regorafenib issue: focus on efficacy and safety in pre-treated metastatic colorectal cancer from a real world experience by Daniel, F, Bannò, E, Belluomini, L, Martella, L R, Lancia, F, Toma, I, Moretti, A, Mentrasti, G, Carandina, I, Marzola, M, Frassoldati, A

Get full text

Estrogen receptor mutation: a new strategy to overcome endocrine resistance by Moretti, A, Lupini, L, Carandina, I, Bassi, C, Martella, L R, Lancia, F, Daniel, F, Belluomini, L, Toma, I, Bannò, E, Nisi, C, Da Ros, L, Querzoli, P, Negrini, M, Frassoldati, A

Get full text

Bone pain control in Castration resistant prostate cancer (CRPC): retrospective analysis of first patients trated with Radium 223 by Toma, I, Lancia, F, Scapoli, D, Frassoldati, A, Panareo, S, Santi, I, Cittanti, C, Bartolomei, M, Daniel, F, Moretti, A, Martella, L R, Belluomini, L, Mentrasti, G

Get full text

Efficacy and safety of immune checkpoint inhibitor nivolumab and radiotherapy combination in advanced NSCLC by Belluomini, L., Fiorica, F., Stefanelli, A., Santini, A., Urbini, B., Daniel, F., Martella, L.R., Toma, I., Lancia, F., Moretti, A., Bannò, E., Giorgi, C., Frassoldati, A.

Get full text

Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface by Belluomini, L., Caliò, A., Giovannetti, R., Motton, M., Mazzarotto, R., Micheletto, C., Infante, M.V., Scarpa, A., Milella, M., Pilotto, S.

Get full text

Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO) by Pizzutilo, E.G., Agostara, A.G., Oresti, S., Signorelli, D., Stabile, S., Lauricella, C., Motta, V., Amatu, A., Ruggieri, L., Brambilla, M., Occhipinti, M., Proto, C., Giusti, R., Filetti, M., Genova, C., Barletta, G., Gelsomino, F., Bennati, C., Siringo, M., Di Fazio, G.R., Russano, M., Montrone, M., Gariazzo, E., Roca, E., Bordi, P., Delmonte, A., Scimone, A., Belluomini, L., Mazzoni, F., Carta, A., Pelizzari, G., Viscardi, G., Morgillo, F., Gelibter, A., Gori, S., Berardi, R., Cortinovis, D., Ardizzoni, A., Veronese, S.M., Sartore-Bianchi, A., Giannetta, L.G., Cerea, G., Siena, S.

“…Osimertinib represents the standard of care for the treatment of advanced non-small-cell lung cancer (NSCLC) harboring classical epidermal growth factor…”
Get full text

CN31 A qualitative study investigating the perception of simultaneous care in nurses by Tregnago, D., Avancini, A., Polato, G., Belluomini, L., Trestini, I., Sposito, M., Insolda, J., Vincenzi, S., Milella, M., Pilotto, S.

Get full text

1510TiP Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant non-small cell lung cancer (NSCLC) according to TP53 mutational status (TEMPLE-2/NCT05785208) by Vitale, A., Pilotto, S., Monaca, F., Belluomini, L., Valente, G., Giannone, L., Berardi, R., Bironzo, P., Ceribelli, A., Galetta, D., Gelibter, A.J., Lugini, A., Roselli, M., Tiseo, M., Scotti, V., Giannarelli, D., Scarpa, A., Milella, M., Tortora, G., Bria, E.

Get full text

2128P exerCise discussion with Oncologist duriNg caNcEr ConsultaTion: The CONNECT study by Pilotto, S., Belluomini, L., Tregnago, D., Trestini, I., Sposito, M., Insolda, J., Landi, L., Carnio, S., Vallone, S., Longo, V., Bafunno, D., Galetta, D., Ricciardi, S., Migliorino, M.R., Mariotti, S., Milella, M., Novello, S., Avancini, A.

Get full text

1857P Choose health, oncological patients centered exercise (CHOiCE): Preliminary findings of a pilot randomized controlled trial by Avancini, A., Scrivano, G., Tregnago, D., Trestini, I., Riva, S.T., Belluomini, L., Menis, J., Valentini, M., Leone, F., Milella, M., Lanza, M., Pilotto, S.

Get full text

1618P Impact of body composition phenotypes on outcome of non-small cell lung cancer patients treated with immunotherapy by Trestini, I., Caldart, A., Dodi, A., Cintoni, M., Sposito, M., Belluomini, L., Menis, J., Vita, E., Sperduti, I., Drudi, A., Aluffi, G., Todesco, M., Tregnago, D., Avancini, A., D'Onofrio, M., Mele, M.C., Tortora, G., Milella, M., Bria, E., Pilotto, S.

Get full text

1430P Psychological status and patient perception during the SARS-CoV-2 vaccination campaign in active oncological patients (pts) by Daniela, T., Avancini, A., Belluomini, L., Trestini, I., Zuliani, S., Sava, T., Gaiani, C., Caldart, A., Casali, M., Benini, L., Zacchi, F., Trevisani, E., Bianchi, F., Riva, S.T., L. del piccolo, Tfaily, A., Rimondini, M., Verlato, G., Pilotto, S., Milella, M.

Get full text

1080P Immune checkpoint blockade therapy affects circulating FLIP-expressing monocytic myeloid-derived suppressor cells (M-MDSC) in non-progressor non-small cell lung cancer patients by Belluomini, L., Frusteri, C., Adamo, A., Pilotto, S., Sartori, G., Insolda, J., Sposito, M., Caligola, S., Giacobazzi, L., Poffe, O., Rizzini, D., Vella, A., Carbone, C., Piro, G., De Sanctis, F., Sartoris, S., Canè, S., Milella, M., Bronte, V., Ugel, S.

Get full text

1355P Clinical trial enrollment among lung cancer patients: A real-world multicenter analysis by Reale, M.L., Capelletto, E., Buttigliero, C., Bordi, P., Ricciardi, S., Belluomini, L., Garbo, E., Leonetti, A., Lombardi, A., Dodi, A., Napoli, V., Casali, M., Soregaroli, D., Insolda, J., Bironzo, P., Tiseo, M., Migliorino, M.R., Pilotto, S., Passiglia, F., Novello, S.

Get full text

1675P Potential effect of adipose tissue distribution on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients (pts) receiving first-line pembrolizumab (PEMBRO) by Trestini, I., Cintoni, M., Sposito, M., Kadrija, D., Dodi, A., Caldart, A., Belluomini, L., Menis, J., Vita, E., Sperduti, I., Drudi, A., Aluffi, G., Tregnago, D., Avancini, A., D'Onofrio, M., Mele, M.C., Tortora, G., Milella, M., Bria, E., Pilotto, S.

Get full text

1640P Impact of COVID-19 vaccination campaign on psychological status in cancer patients (pts) by Tregnago, D., Pilotto, S., Belluomini, L., Menis, J., Fiorio, E., Pavarana, M., Casali, M., Benini, L., Zacchi, F., Caldart, A., Trevisani, E., Trestini, I., Avancini, A., Cafaro, D., Cadorin, C., Rimondini, M., Del Piccolo, L., Zuliani, S., Milella, M.

Get full text

1831P Role of body composition (bc) in advanced non-small cell lung cancer (NSCLC) patients receiving first-line pembrolizumab (pembro) by Pilotto, S., Trestini, I., Sperduti, I., Sposito, M., Kadrija, D., Dodi, A., Cintoni, M., Drudi, A., Aluffi, G., Belluomini, L., Sartori, G., Casali, M., Lombardo, F., Tregnago, D., Avancini, A., Carbognin, L., D'Onofrio, M., Mele, M.C., Bria, E., Milella, M.

Get full text